NCT06753981View on ClinicalTrials.gov

Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study

RecruitingOBSERVATIONAL
Enrollment

48

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

November 14, 2026

Study Completion Date

February 14, 2027

Conditions
Arterial Pulmonary Hypertension (PAH)
Interventions
DRUG

Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs

Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs Including macitentan sildenafil/tadalafil or riociguat selexipag/epoprostenol.

Trial Locations (1)

250014

RECRUITING

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China, Jinan

All Listed Sponsors
collaborator

Chinese Academy of Medical Sciences, Fuwai Hospital

OTHER

collaborator

Jianghan University Affiliated Hospital

UNKNOWN

lead

Qianfoshan Hospital

OTHER